Showing 1691-1700 of 3038 results for "".
- Emmecell Announces Advancements of Non-Surgical Cell Therapy for Corneal Edemahttps://modernod.com/news/emmecell-announces-advancements-of-non-surgical-cell-therapy-for-corneal-edema/2482551/Emmecell announced positive results from its US multicenter phase 1 trial evaluating EO2002, a non-surgical cell therapy for corneal edema. The randomized, double-masked trial showed significant improvement in patients’ best corrected visual acuity (BCVA), reduction in central cor
- Life Biosciences Presents New Data on Novel Gene Therapy at AAOhttps://modernod.com/news/life-biosciences-presents-new-data-on-novel-gene-therapy-at-aao/2482505/Life Biosciences announced new data at the 2024 American Association of Ophthalmology (AAO) annual meeting on its gene therapy for optic neuropathies. According to Life Biosciences, the data replicates earlier findings in nonhuman primates (NHPs) and provides insights into the dosing and tim
- Haag-Streit to Host "Biometry Focus Month 2024" with Weekly Webinars in Novemberhttps://modernod.com/news/haag-streit-to-host-biometry-focus-month-2024-with-weekly-webinars-in-november/2482492/Haag-Streit has announced the return of "Biometry Focus Month 2024" in November. The event will feature a series of live webinars every Thursday from November 7 to November 28, 2024. Each session will address critical topics in biometry, offering cataract and refractive surgeons ke
- Novaliq and Laboratoires Théa Announce EU Approval for Vevizye for Dry Eye Diseasehttps://modernod.com/news/novaliq-and-laboratoires-thea-announce-partnership-and-eu-approval-for-vevizye/2482466/Novaliq and Laboratoires Théa announced the European Commission’s approval of Vevizye (ciclosporin 0.1% eye drops solution) for the treatment of moderate to severe dry eye disease (DED) in adults unresponsive to tear substitutes. Vevizye is based on Nova
- Ocumension Therapeutics Secures Deal with Alcon to Expand Dry Eye Treatment Portfolio in Chinahttps://modernod.com/news/ocumension-therapeutics-secures-deal-with-alcon-to-expand-dry-eye-treatment-portfolio-in-china/2482395/China-based ophthalmic pharmaceutical company Ocumension Therapeutics announced an agreement with Alcon under which OcuMension will acquire or secure commercialization rights in China to a portfolio of Alcon’s dry eye treatments and procedural drops, including establishe
- Contact Lens Institute Opens Nominations for Second Annual Culture Awardshttps://modernod.com/news/contact-lens-institute-opens-nominations-for-second-annual-culture-awards/2482394/The Contact Lens Institute (CLI) has announced that nominations for the second annual CLI Culture Awards are now open, with submissions being accepted through October 1, 2024. This program aims to recognize eye care professionals who are committed to fostering a positive culture around contact le
- Novaliq Receives Positive CHMP Opinion for Vevizye in Dry Eye Diseasehttps://modernod.com/news/novaliq-receives-positive-chmp-opinion-for-vevizye-in-dry-eye-disease/2482383/Novaliq announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization in the European Union for dry eye drug Vevizye. Vevizye is intended for the treatment
- Nova Eye to Feature Several Presentations and Posters Related to iTrack Canaloplasty at 2024 ESCRS Annual Congresshttps://modernod.com/news/nova-eye-to-feature-several-presentations-and-posters-related-to-itrack-canaloplasty-at-2024-escrs-annual-congress/2482374/Nova Eye Medical has announced that the company’s proprietary canaloplasty technology platform (iTrack and iTrack Advance) will be featured in numerous presentations and posters during the official scientific program of the European Society of Cataract and Refractive Surgeons
- Notal Vision Announces Results From Prospective Trial Using Home-Based OCThttps://modernod.com/news/notal-vision-announces-results-from-prospective-trial-using-home-based-oct/2482331/Notal Vision announced the results from the first prospective clinical trial using home-based optical coherence tomography (OCT) to manage wet age-related macular degeneration (AMD) patients in an investigational setting. The results, which were published in Retina, demonstrated a
- Nominations Now Being Accepted for Neuro-Optometric Rehabilitation Association Awardshttps://modernod.com/news/nominations-now-being-accepted-for-neuro-optometric-rehabilitation-association-awards/2482308/Nominations are now being accepted by the Neuro-Optometric Rehabilitation Association, International (NORA) for the following awards, which acknowledge individuals and organizations for important contributions to the area of neuro-optometric rehabilitation. The Advancement of Neur